Oramed Pharmaceuticals sell nvestor
Start price
28.11.20
/
50%
€3.80
Target price
28.11.21
€1.00
Performance (%)
201.58%
End price
26.06.21
€11.46
Summary
This prediction ended on 26.06.21 with a price of €11.46. The price for Oramed Pharmaceuticals massively increased, which is bad news for the SELL prediction by nvestor. nvestor has 50% into this predictionOramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oramed Pharmaceuticals | 2.065% | 2.065% | 8.382% | -72.475% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |